Sarah A. Frech

Corporate Officer/Principal presso IOMAI CORPORATION

Consumer Services

Health Technology

Profilo

Dr. Sarah A.
Frech is Vice President-Clinical Development at Intercell USA, Inc. and Vice President-Clinical Research at Vtesse, Inc. She received her undergraduate degree from Dartmouth College, a graduate degree from the Johns Hopkins Bloomberg School of Public Health, and a doctorate degree from Washington State University.

Posizioni attive di Sarah A. Frech

Società	Posizione	Inizio
IOMAI CORPORATION	Corporate Officer/Principal	-

Tutte le posizioni attive di Sarah A. Frech

Precedenti posizioni note di Sarah A. Frech

Società	Posizione	Fine
Vtesse, Inc. Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Sarah A. Frech

Formazione di Sarah A. Frech

Dartmouth College	Undergraduate Degree
Washington State University	Doctorate Degree
Johns Hopkins Bloomberg School of Public Health	Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Sarah A. Frech

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Intercell USA, Inc. Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.	Health Technology
Vtesse, Inc. Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.	Health Technology